These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 9819099)

  • 1. The antiatherogenic role of high-density lipoprotein cholesterol.
    Kwiterovich PO
    Am J Cardiol; 1998 Nov; 82(9A):13Q-21Q. PubMed ID: 9819099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiatherogenic effect of high density lipoprotein].
    Turczyn B; Skoczyńska A
    Postepy Hig Med Dosw; 2002; 56(4):499-520. PubMed ID: 12418415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of oxidized phosphatidylcholines formed in oxidized low density lipoprotein by lecithin-cholesterol acyltransferase.
    Itabe H; Hosoya R; Karasawa K; Jimi S; Saku K; Takebayashi S; Imanaka T; Takano T
    J Biochem; 1999 Jul; 126(1):153-61. PubMed ID: 10393333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration.
    Forte TM; Oda MN; Knoff L; Frei B; Suh J; Harmony JA; Stuart WD; Rubin EM; Ng DS
    J Lipid Res; 1999 Jul; 40(7):1276-83. PubMed ID: 10393212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport.
    El Khoury P; Waldmann E; Huby T; Gall J; Couvert P; Lacorte JM; Chapman J; Frisdal E; Lesnik P; Parhofer KG; Le Goff W; Guerin M
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):285-94. PubMed ID: 26681758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation?
    Quintão EC
    Atherosclerosis; 1995 Jul; 116(1):1-14. PubMed ID: 7488324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High density associated enzymes: their role in vascular biology.
    Navab M; Hama SY; Hough GP; Hedrick CC; Sorenson R; La Du BN; Kobashigawa JA; Fonarow GC; Berliner JA; Laks H; Fogelman AM
    Curr Opin Lipidol; 1998 Oct; 9(5):449-56. PubMed ID: 9812199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells.
    Martin G; Pilon A; Albert C; Vallé M; Hum DW; Fruchart JC; Najib J; Clavey V; Staels B
    Eur J Biochem; 1999 Apr; 261(2):481-91. PubMed ID: 10215860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
    Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
    Briand F; Thieblemont Q; Muzotte E; Sulpice T
    Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
    Johnston N; Jernberg T; Lagerqvist B; Siegbahn A; Wallentin L
    Am J Cardiol; 2006 Mar; 97(5):640-5. PubMed ID: 16490429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters.
    Rhainds D; Brodeur M; Lapointe J; Charpentier D; Falstrault L; Brissette L
    Biochemistry; 2003 Jun; 42(24):7527-38. PubMed ID: 12809509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.
    De Geest B; Stengel D; Landeloos M; Lox M; Le Gat L; Collen D; Holvoet P; Ninio E
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):E68-75. PubMed ID: 11031226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.
    Gillard BK; Raya JL; Ruiz-Esponda R; Iyer D; Coraza I; Balasubramanyam A; Pownall HJ
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1714-21. PubMed ID: 23640486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
    Knopp RH; Paramsothy P; Atkinson B; Dowdy A
    Am J Cardiol; 2008 Apr; 101(8A):48B-57B. PubMed ID: 18375242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.